USA: +1 617 939 9497 | UK: +44 2039 962936 | EU: +34 607 939 266
Select Page

CRO for Gynecologic Cancer Clinical Trials

What are gynecologic cancers?

Gynecologic cancers are tumors that develop in a woman’s reproductive organs. Gynecologic cancers appear in different locations within a woman’s pelvis.

What are the different types of gynecological cancers?

The main gynecological cancers are ovarian, endometrial, cervical, vaginal, and vulvar cancers. Endometrial (uterine) cancer is the most commonly diagnosed gynecologic cancer in the United States.

How many women are affected by gynecological cancers?

In the United States, it is estimated that 21,410 women will be diagnosed with ovarian cancer every year. Most of these cases (90%) will be high-grade serous ovarian cancers (HGSC). Around 66,570 women will be diagnosed with uterine (endometrial) cancer, and 14,480 will be diagnosed with invasive cervical cancer yearly [1].

What are the current treatments for gynecologic cancers?

Surgical removal is the standard initial approach for primary gynecologic cancers. Then, there are various drugs used to treat gynecological malignancies in different stages, such as bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), trabectedin, olaparib, niraparib, and rucaparib, among others.

Survival of gynecologic cancer patients

The 5-year survival rate for women with all types of ovarian, fallopian tube, and peritoneal cancers is 49%. If ovarian and fallopian tube cancers are diagnosed and treated before they spread, the general 5-year survival rate is 93%. The 5-year survival rate for women with uterine and cervical cancer is 81% and 66% respectively [1].

Sofpromed: The gynecologic cancer expert CRO

Sofpromed is an oncology-focused CRO with wide expertise in managing cancer trials, including gynecological tumors (particularly ovarian and endometrial cancer). Contact us to find out how we can help with your next gynecologic cancer trial.